| |APRIL 202619PAIN MANAGEMENT MEDICATION & 2026TOP 10ORTHOPAEDIC MANUFACTURERS AND SUPPLIERSour offerings reflect a broader belief that long-term pain medications, combined with lifestyle modification, should be explored before invasive interventionskey starting materials, helping sustain margins without compromising reliability.Delivery on the ground remains a defining strength. Field teams are trained as Clinical Advisors, capable of discussing therapy rationale rather than just product features. Awareness camps, trial packs, and regular doctor interactions are part of this model. Retail partners receive guidance on counseling patients who rely on long-term pain medications, helping reduce drop-off and misuse.In pediatrics, the approach is equally measured. Conditions such as Juvenile Idiopathic Arthritis, one of the most common chronic childhood conditions, are often mistaken for growth pains or sports injuries. Since children may not describe joint stiffness clearly, diagnosis is delayed. Feedback from clinicians suggests that topical options like Jrumax Oil have shown benefits in such cases due to better tolerance.Much of this discipline was shaped earlier through gastroenterology. The launch of the blockbuster brand Carminozyme created a base, followed by expansion into acid management, chronic disease management such as IBS, and lifestyle-related conditions. Offline promotion, CRM, and awareness campaigns played a key role in sustaining growth. "In respiratory care, we remain strong, with long-standing brands prescribed widely, especially in Eastern India," notes Dr Shyamasree Choudhury Sarkar.Shaping the Future of Pain Management in IndiaThe long-term vision of the company reflects where pain care in India is headed. There is a clear intent to build leadership in natural-first pain management by thoughtfully blending modern pharmaceutical molecules with standardized Ayurvedic extracts, especially for chronic conditions such as osteoarthritis that demand sustained care. As access to healthcare expands beyond metros, growth will increasingly come from tier-2 and tier-3 markets, where a hybrid-access model can bridge gaps in awareness and continuity. Rather than chasing speed or scale, the emphasis remains on staying clinically relevant, responsive to change, and closely aligned with how doctors and patients actually manage pain over time. PO
< Page 9 | Page 11 >